Piper Jaffray analyst Matt O'Brien acknowledges the near-term issues Abiomed is encountering but continues to believe in Impella and the company. The analyst views the positive Protect III study as a potential shot in the arm for the protected PCI business. Additionally, the headwinds surrounding low-risk TAVR enthusiasm and need for more sales leadership will likely abate in the coming months, which should result in more uptake of Impella, he contends, adding that he heard positive clinician feedback on the recently released 5.5 product and continued progress in developing a smaller insertion sheath and ECP and enrolling the STEMI trial. O'Brien reiterates an Overweight rating and a $240 price target on the shares.